Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.54 |
| ▸ | FPR2 | P25090 | 3/20 | 0.52 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.39 |
| ▸ | FPR1 | P21462 | 2/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4475463 | 0.85 | F10 (0.54) | F10FPR2BRD9FPR1AKR1C3 | |
| SCHEMBL4490944 | 0.85 | F10 (0.54) | F10FPR2BRD9FPR1AKR1C3 | |
| SCHEMBL4464011 | 0.84 | FPR2 (0.53) | F10FPR2FPR1AKR1C3CYP3A4 | |
| SCHEMBL4470698 | 0.79 | F10 (0.55) | F10 | |
| SCHEMBL4465550 | 0.77 | AKR1C3 (0.48) | FPR2FPR1AKR1C3ALDH1A1 | |
| SCHEMBL77996 | 0.76 | BRD9 (0.47) | F10BRD9AKR1C3CYP3A4CYP2C9 | |
| SCHEMBL21515221 | 0.75 | BRD9 (0.49) | F10BRD9AKR1C3CYP3A4CYP2C9 | |
| SCHEMBL5421060 | 0.74 | BRD9 (0.46) | F10BRD9AKR1C3CYP3A4CYP2C9 | |
| SCHEMBL23168339 | 0.74 | F10 (0.43) | F10FPR2BRD9AKR1C3CYP3A4 | |
| SCHEMBL4558265 | 0.73 | F10 (0.54) | F10FPR2FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157470-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | claimed |
| US-7524863-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-28 | — | — | US | disclosed |
| US-7157470-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1501798-A4 | SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060247243-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | SMALLHEER JOANNE M | 2006-11-02 | — | — | US | disclosed |
| EP-1501798-A2 | SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004041776-A2 | SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040006062-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247243-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | TFPI, SPINT2, F5 | F10 38/4885FPR2 3867/4885BRD9 1655/4885 |
| US-20040006062-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | TFPI, SPINT2, PRSS1 | F10 31/4885FPR2 3872/4885BRD9 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.